Bio-Raid Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Bio-Raid General Information

Description

Developer of CAR-T cell immunotherapy. The company develops CAR-T cell immunotherapy to treat blood and solid tumors, and HIV diseases, committing to promoting cellular immunotherapy technology to clinical application as soon as possible

Contact Information

Website
www.bio-raid.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Floor 4&5, Building 3, Phase 3.1, Wuhan Optics Valley International Biomedical Accelerator
  • No. 388, Gaoxin 2nd Road, East Lake New Technology Development Zone
  • Wuhan, Hubei
  • China
+86 027
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Floor 4&5, Building 3, Phase 3.1, Wuhan Optics Valley International Biomedical Accelerator
  • No. 388, Gaoxin 2nd Road, East Lake New Technology Development Zone
  • Wuhan, Hubei
  • China
+86 027

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bio-Raid Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 11-Jan-2023 Completed Generating Revenue
3. Later Stage VC 12-Apr-2022 Completed Clinical Trials - General
2. Early Stage VC 29-Sep-2018 $2.83M Completed Clinical Trials - General
1. Early Stage VC 28-Dec-2016 $2.83M $2.83M Completed Clinical Trials - General
To view Bio-Raid’s complete valuation and funding history, request access »

Bio-Raid Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Bio-Raid Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190389940-A1 Construction and application of recombinant gene for chimeric antigen receptor for treating hiv infection Inactive 28-Jun-2017
EP-3511347-A1 Construction of recombined gene of chimeric antigen receptor for treatment of hiv infection, and application thereof Inactive 28-Jun-2017
EP-3511347-A4 Construction of recombined gene of chimeric antigen receptor for treatment of hiv infection, and application thereof Inactive 28-Jun-2017
WO-2019000620-A1 Construction of recombined gene of chimeric antigen receptor for treatment of hiv infection, and application thereof Inactive 28-Jun-2017 C07K16/1145

Bio-Raid Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Xiaoxiang Capital Venture Capital Minority
Xingxiang Investment Holding Group Asset Manager Minority
To view Bio-Raid’s complete investors history, request access »

Ready to get started?

Request a free trial

Bio-Raid FAQs

  • When was Bio-Raid founded?

    Bio-Raid was founded in 2014.

  • Where is Bio-Raid headquartered?

    Bio-Raid is headquartered in Wuhan, China.

  • What industry is Bio-Raid in?

    Bio-Raid’s primary industry is Drug Discovery.

  • Is Bio-Raid a private or public company?

    Bio-Raid is a Private company.

  • What is Bio-Raid’s current revenue?

    The current revenue for Bio-Raid is .

  • How much funding has Bio-Raid raised over time?

    Bio-Raid has raised $2.83M.

  • Who are Bio-Raid’s investors?

    Xiaoxiang Capital and Xingxiang Investment Holding Group have invested in Bio-Raid.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process